Abstract
Connective tissue growth factor (CTGF or CCN2), which belongs to the CCN family, is a secreted protein. It has been implicated in various biological processes, such as cell proliferation, migration, angiogenesis, and tumorigenesis. In this study, we found that CTGF expression level was elevated in primary papillary thyroid carcinoma (PTC) samples and correlated with clinical features, such as metastasis, tumor size, and clinical stage. Overexpression of CTGF in PTC cells accelerated their growth in liquid culture and soft agar as well as protecting PTC cells from apoptosis induced by IFN-gamma treatment. Downregulation of CTGF in PTC cells inhibits cell growth in liquid culture and soft agar and induces the activation of caspase pathway and sensitized PTC cells to apoptosis. Our data suggest that CTGF plays an important role in PTC progression by supporting tumor cell survival and drug resistance, and CTGF may be used as a potential tumor marker for PTC diagnosis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the US, 1985–1995 [see comments] (translated from English). Cancer. 1998;83(12):2638–48 (in English).
Liu S, Semenciw R, Ugnat AM, Mao Y. Increasing thyroid cancer incidence in Canada, 1970–1996: time trends and age-period-cohort effects. Br J Cancer. 2001;85(9):1335–9.
Farid NR. P53 mutations in thyroid carcinoma: tidings from an old foe. J Endocrinol Investig. 2001;24(7):536–45.
Prante O et al. Regulation of uptake of 18F-FDG by a follicular human thyroid cancer cell line with mutation-activated K-ras. J Nucl Med. 2009;50(8):1364–70.
Christine J et al. BRAFV600E mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer. Surgery. 2010;148(6):1139–46.
McIver B, Grebe SK, Eberhardt NL. The PAX8/PPAR gamma fusion oncogene as a potential therapeutic target in follicular thyroid carcinoma. Curr Drug Targets Immune Endocr Metabol Disord. 2004;4(3):221–34.
Anna G et al. Prevalence of RET/PTC rearrangement in benign and malignant thyroid nodules and its clinical application. Endocr J. 2011;58(1):31–8.
Asmis LM, Gerber H, Kaempf J, Studer H. Epidermal growth factor stimulates cell proliferation and inhibits iodide uptake of FRTL-5 cells in vitro. J Endocrinol. 1995;145(3):513–20.
Nishida T et al. CCN family 2/connective tissue growth factor (CCN2/CTGF) regulates the expression of Vegf through Hif-1alpha expression in a chondrocytic cell line, HCS-2/8, under hypoxic condition. Bone. 2009;44(1):24–31.
Bork P. The modular architecture of a new family of growth regulators related to connective tissue growth factor. FEBS Lett. 1993;327(2):125–30.
Perbal B. CCN proteins: multifunctional signalling regulators. Lancet. 2004;363(9402):62–4.
Yang F et al. Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis. Cancer Res. 2005;65(19):8887–95.
Xie D et al. Levels of expression of CYR61 and CTGF are prognostic for tumor progression and survival of individuals with gliomas. Clin Cancer Res. 2004;10(6):2072–81.
Wang MY et al. Connective tissue growth factor confers drug resistance in breast cancer through concomitant up-regulation of Bcl-xL and cIAP1. Cancer Res. 2009;69(8):3482–91.
Deng YZ et al. Connective tissue growth factor is overexpressed in esophageal squamous cell carcinoma and promotes tumorigenicity through beta-catenin-T-cell factor/Lef signaling. J Biol Chem. 2007;282(50):36571–81.
Chen PP et al. Expression of Cyr61, CTGF, and WISP-1 correlates with clinical features of lung cancer. PLoS ONE. 2007;2(6):e534.
Lin BR et al. Connective tissue growth factor inhibits metastasis and acts as an independent prognostic marker in colorectal cancer. Gastroenterology. 2005;128(1):9–23.
Shakunaga T et al. Expression of connective tissue growth factor in cartilaginous tumors. Cancer. 2000;89(7):1466–73.
Yin D et al. CTGF associated with oncogenic activities and drug resistance in glioblastoma multiforme (GBM) (translated from English) Int J Cancer 2010 (in English)
Selzer E, Wilfing A, Sexl V, Freissmuth M. Effects of type I-interferons on human thyroid epithelial cells derived from normal and tumour tissue (translated from English). Naunyn Schmiedebergs Arch Pharmacol. 1994;350(3):322–8 (in English).
Junko A et al. Down-regulation of transcription elogation factor A (SII) like 4 (TCEAL4) in anaplastic thyroid cancer. BMC Cancer. 2006;6:260. doi:10.1186/1471-2407-6-260.
Liu LY, Han YC, Wu SH, Lv ZH. Expression of connective tissue growth factor in tumor tissues is an independent predictor of poor prognosis in patients with gastric cancer (translated from English). World J Gastroenterol. 2008;14(13):2110–4 (in English).
Chang CC et al. Connective tissue growth factor and its role in lung adenocarcinoma invasion and metastasis (translated from English). J Natl Cancer Inst. 2004;96(5):364–75 (in English).
Chen PS et al. CTGF enhances the motility of breast cancer cells via an integrin-alphavbeta3-ERK1/2-dependent S100A4-upregulated pathway (translated from English). J Cell Sci. 2007;120(Pt 12):2053–65 (in English).
Alvarez H et al. Serial analysis of gene expression identifies connective tissue growth factor expression as a prognostic biomarker in gallbladder cancer (translated from English). Clin Cancer Res. 2008;14(9):2631–8 (in English).
Conflicts of interest
None
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Cui, L., Zhang, Q., Mao, Z. et al. CTGF is overexpressed in papillary thyroid carcinoma and promotes the growth of papillary thyroid cancer cells. Tumor Biol. 32, 721–728 (2011). https://doi.org/10.1007/s13277-011-0173-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13277-011-0173-6